UTHR
United Therapeutics Corporation
NASDAQ · USHealthcareBiotechnology
$529.34-1.18%
Price as of Jul 20, 2026
UTHR financials
United Therapeutics Corporation financial statements
Annual and quarterly income statement, balance sheet and cash-flow history. On small screens, start with four periods and expand the table when needed.
| Metric | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|
| Income statement | ||||
| Revenue | $3.2B | $2.9B | $2.3B | $1.9B |
| Cost of revenue | $384.4M | $309.7M | $257.5M | $146.7M |
| Gross profit | $2.8B | $2.6B | $2.1B | $1.8B |
| Operating expenses | $1.3B | $1.2B | $885.1M | $809.9M |
| Operating income | $1.5B | $1.4B | $1.2B | $979.7M |
| Net income | $1.3B | $1.2B | $984.8M | $727.3M |
| EBITDA | $1.8B | $1.7B | $1.4B | $1.0B |
| Basic EPS | $30.13 | $26.44 | $21.04 | $15.98 |
| Diluted EPS | $27.86 | $24.64 | $19.81 | $15.00 |
| Balance sheet | ||||
| Cash & equivalents | $1.6B | $1.7B | $1.2B | $961.2M |
| Total assets | $7.9B | $7.4B | $7.2B | $6.0B |
| Total liabilities | $783.8M | $920.0M | $1.2B | $1.2B |
| Stockholders’ equity | $7.1B | $6.4B | $6.0B | $4.8B |
| Total debt | $37.6M | $300.0M | $700.0M | $800.0M |
| Net debt | -$1.5B | -$1.4B | -$507.7M | -$161.2M |
| Cash flow | ||||
| Operating cash flow | $1.6B | $1.3B | $978.0M | $802.5M |
| Capital expenditure | -$520.5M | -$246.5M | -$230.4M | -$138.8M |
| Free cash flow | $1.0B | $1.1B | $747.6M | $663.7M |
| Dividends paid | $0.00 | $0.00 | $0.00 | $0.00 |
| Share repurchases | -$1.0B | -$1.0B | -$13.8M | -$11.4M |